Advertising and Promotion for the Pharmaceutical, Medical Device, Biologics, and Veterinary Medicine Industries

Advertising and Promotion for the Pharmaceutical, Medical Device, Biologics, and Veterinary Medicine Industries

Speaking Engagement
On September 17th and 18th, the Food and Drug Law Institute (FDLI) hosted approximately 300 attendees at its annual conference on "Advertising and Promotion for the Pharmaceutical, Medical Device, Biologics, and Veterinary Medicine Industries."The annual conference, one of the largest of its kind dedicated to advertising and promotional issues for FDA-regulated products, provides a forum for FDA and other government regulators, company officials and industry experts to share news, insights and analysis about legal, regulatory and policy developments regarding the promotion of pharmaceuticals and other products subject to FDA oversight. WilmerHale Partner Scott Lassman was a panelist at this event. Other panelists included Dr. Bruce Burlington, formerExecutive Vice President of Wyeth Pharmaceuticals and former head ofFDA'sCenter for Devices and RadiologicalHealth, and John Kamp, Executive Director of the Coalition for Healthcare Communication.

Read More About the Event

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.